Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries
- 229 Downloads
Women diagnosed with breast cancer display higher propensity to develop second primary cancer in the contralateral breast (CBC). Identification of patients with increased risk of CBC and understanding relationships between hormone receptor (HR) statuses of the first and second breast cancers is desirable for endocrine-based prevention strategies.
Using 1992–2012 data from 13 SEER registries, the risk of developing CBC was determined as ratio of observed and expected second breast cancers (SIR). Association between HR statuses was examined by exploratory data analysis and multivariable logistic regression. Results: Women with ER-positive and ER-negative breast cancers have increased risk of developing CBC with SIR values 2.09 (CI 95 = 1.97–2.21) and 2.40 (CI 95 = 2.18–2.63), respectively. ER statuses of the CBC are moderately positively associated. In metachronous CBC, most cases with ER-positive first cancers had ER-positive second breast cancers (81.6 %; CI 95 = 80.2–82.9 %); however, considerable proportion of cases with ER-negative first cancers had ER-positive second cancers (48.8 %; CI 95 = 46.2–51.4 %).
Some women with ER-negative breast cancers may benefit from endocrine-based prevention of ER-positive CBC.
KeywordsBilateral breast cancer Contralateral breast cancer Synchronous breast cancer Metachronous breast cancer Estrogen receptor Estrogen receptor-negative breast cancers
Compliance with ethical standards
Conflict of interest
Authors declare no conflict of interest relevant to the subject of this article.
Data from the SEER have no personal identifying information and therefore ethical approval not required.
- 2.Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER cancer statistics review (CSR) 1975–2012. Bethesda: National Cancer Institute; 2015.Google Scholar
- 3.American Cancer Society. Breast cancer facts and figures 2013–2014. Atlanta: American Cancer Society; 2013.Google Scholar
- 6.Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134:e48–72.PubMedGoogle Scholar
- 7.Early Breast Cancer Trialists’ Collaborative Group, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.CrossRefGoogle Scholar
- 9.Rosen PP. Invasive mammary carcinoma. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors. Diseases of the Breast. Philadelphia: Lippincott-Raven; 1996. p. 393.Google Scholar
- 20.Brennan ME, Houssami N, Lord S, Macaskill P, Irwig L, Dixon JM, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol. 2009;27:5640–9.CrossRefPubMedGoogle Scholar